<DOC>
	<DOC>NCT01704755</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) coadministered with ribavirin (RBV) in hepatitis C virus (HCV) genotype 1-infected adults with compensated cirrhosis.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis</brief_title>
	<detailed_description>During the treatment period of the study, participants received treatment with ABT-450/ritonavir/ABT-267 and ABT-333 coadministered with RBV for either 12 or 24 weeks. Upon completing the treatment period or premature discontinuation of the treatment period, participants entered a 48-week post-treatment period.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Females must be practicing specific forms of birth control on study treatment, or be postmenopausal for more than 2 years or surgically sterile Male or female between 18 and 70 years, inclusive, at time of Screening. Chronic HCVinfection prior to study enrollment. Screening laboratory result indicating HCV genotype 1infection. Compensated cirrhosis defined as a ChildPugh Score of less than or equal to 6 at Screening Subject has plasma HCV RNA level greater than 10,000 IU/mL at Screening. Significant liver disease with any cause other than HCV as the primary cause Positive test result for Hepatitis B surface antigen (HBsAg) or antiHuman Immunodeficiency virus antibody (HIV Ab) at screening. Prior therapy with direct acting antiviral agents for the treatment of HCV, including telaprevir and boceprevir. Any current or past clinical evidence of ChildPugh B or C Classification or clinical history of liver decompensation including ascites (noted on physical exam), variceal bleeding or hepatic encephalopathy. A positive screening ultrasound for hepatocellular carcinoma (HCC) confirmed with a subsequent CT Scan or MRI during the screening period.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Cirrhosis</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Child Pugh A</keyword>
	<keyword>Compensated Cirrhosis</keyword>
	<keyword>Hepatitis C Genotype 1</keyword>
	<keyword>Cirrhotic</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>ombitasvir</keyword>
	<keyword>paritaprevir</keyword>
	<keyword>dasabuvir</keyword>
	<keyword>Interferon-Free</keyword>
	<keyword>Viekira Pak</keyword>
</DOC>